Cell therapy weekly: potential biomarker may help screen donor MSCs for those that are most scalable

Written by RegMedNet

Cell therapy weekly

This week: TreeFrog Therapeutics (Pessac, France) announces a new facility for scaling up induced pluripotent stem cell (iPSC)-based cell therapy manufacturing processes, Qkine (Cambridge, UK) successfully closes £1.5 million in series A investment funding and Innovent Biologics (Suzhou, China) and Roche (Basel, Switzerland) have announced a research and development collaboration. The news highlights: Potential biomarker may help screen donor MSCs for those that are most scalable New facility for scaling up iPSC-based cell therapy manufacturing processes opens in France Protein manufacturer for stem cell and regenerative medicine applications closes £1.5 million funding to accelerate global scale-up of commercial operations Collaboration...

To view the full article, please register now for access

It's completely free